Home > News > Latest > Modern Meadow and BASF Collaborate to Create a New Innovative Animal-Free Enriched Material

Industrial Impact

Modern Meadow and BASF Collaborate to Create a New Innovative Animal-Free Enriched Material

Modern Meadow, a purpose-driven biotechnology company, is proud to announce its strategic partnership with BASF, a leading global chemical company, to embark on a collaboration to revolutionize the material industry. This strategic collaboration will bring together the cutting-edge biofabrication expertise of Modern Meadow with BASF's renowned Ultramid® Ccycled® material, paving the way for the creation of a modern, sustainable, and animal-free material of the future.

Bio-VERA™, a game-changing substrate engineered by Modern Meadow, integrates BASF's Ultramid® Ccycled® solution and is powered with Modern Meadow Bio-Alloy™ technology. By combining post-consumer waste and bio-renewable technologies, this innovative alternative will deliver a highly sustainable, luxurious material with exceptional performance capabilities.

Bio-VERA™ represents a remarkable advancement in the quest for sustainable biomaterials, as it reduces reliance on traditional animal-based sources while minimizing the environmental impact of production using plant-based and recycled feedstock. Modern Meadow's expertise in materials science and bio-based R&D and BASF's chemical expertise and commitment to future-oriented mass-balanced high-quality innovation will offer new possibilities ushering in a new era of sustainability and responsible consumption.

The driving force behind this partnership lies in the shared commitment of both companies to address the challenges posed by conventional material production. "We are thrilled to partner with BASF on this transformative journey toward sustainable biomaterials," said Catherine Roggero-Lovisi, CEO of Modern Meadow. "We have a unique opportunity to create a material that not only meets the demands of the modern world but also helps protect our environment using traceable plant-based and recycled feedstock to avoid animal and virgin petrochemical inputs and that at the beginning of the material development as a drop-in solution."

This alliance sets the stage for the development of high-performing, highly sustainable biomaterials that have the potential to transform various sectors, including fashion, automotive, and consumer goods.

About Modern Meadow

Modern Meadow is a sustainable bio-design technology company that uses nature-inspired proteins to develop solutions that reduce our reliance on petrochemical and animal-derived inputs. Its scalable products drop into existing manufacturing processes, allowing partners to bring sustainable goods to market quickly and without high upfront costs. The company aims to drive innovation in sustainability and create new solutions for the world's most pressing challenges.

Spotlight

Other News

Medical

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Personalis, Inc. | February 05, 2024

Personalis, Inc. a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform. “We have built a unique pharma channel based on our industry-leading tissue and MRD assays and ClearNote Health’s blood-based epigenomic approach is complementary to our offering as it helps our customers deepen their understanding of a patient’s response to immunotherapies,” said Chris Hall, CEO and President of Personalis. “Commercial partnerships such as this broaden our portfolio and are expected to appeal to a wide range of biopharma customers and accelerate our revenue growth.” Echoing this sentiment, Dave Mullarkey, CEO of ClearNote Health, remarked, “Partnering with Personalis presents an excellent opportunity to bring our 5hmC technology to the forefront of cancer research. This alliance is a testament to the synergy between our two companies, enabling us to expand our reach and significantly impact the biopharmaceutical industry. Together, we can accelerate the development of personalized therapies and make a real difference in the lives of patients.” ClearNote Health’s Epigenomics Platform represents a groundbreaking advance in cancer detection, offering real-time insights into disease-specific pathways. By tracking changes in 5hmC levels coupled with artificial intelligence-based analytical methods, the platform can detect cancer earlier, monitor disease progression, understand mechanisms of resistance, and identify promising drug targets and biomarkers. These insights are invaluable for optimizing drug development programs and delivering more effective treatments to patients. The Epigenomics Platform identifies changes in gene activation and gene regulation by labeling specific changes in the 5hmC landscape from plasma-derived cell-free DNA. This rich biological information, as part of clinical trials, enables the monitoring of cancer therapies in real time and contributes to an understanding of drug resistance mechanisms. The partnership marks a pivotal moment in cancer research, leveraging the strengths of both companies to offer unparalleled solutions in the biopharmaceutical industry. About ClearNote Heath, Inc. ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives. Utilizing a standard blood draw, the company applies its proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases, ClearNote Health identifies cancers before they progress and when patients are most likely to benefit from treatment. ClearNote Health’s first commercially available test is the Avantect™ Pancreatic Cancer Test, which detects the presence of pancreatic cancer signals in patients at high risk of the disease, including those recently diagnosed with Type 2 diabetes. ClearNote Health is headquartered in San Diego, with additional presence in the San Francisco Bay area and internationally. The company’s CLIA- and CAP-accredited laboratory is located in San Diego, Calif. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.